Practical reference · maintained document

Access notes: New Zealand

Regional › European Union EMA personal import cost per milligramIn maintenance

Maintainers: ppm_error, hana.sato, q.zhao_qa, customs_ledger, mira.patel Last updated 3 May 2026 Next review due 13 November 2026 329 words · 5 revisions

Sourced from a discussion. This document was promoted out of [2026 update] EU-wide position versus national implementation (solved), in European Union. That topic links back here, and corrections raised there flow into this page.

Regulator, prescription status, reimbursement position and practical access route for New Zealand. Every claim dated, because this changes constantly.

Scope and expiry

Practical access notes for New Zealand: who regulates, what prescription status applies, how reimbursement is decided, and what route people actually use.

This page expires. Access conditions in this field have changed several times a year since 2023. The review date at the top of this page is the date it was last checked against primary sources. If you are making a decision, read the current official document rather than this page.

Regulatory and prescription position

Medsafe is the regulator and Pharmac makes funding decisions. Products in this class require a prescription.

Coverage and cost

Pharmac funding decisions are made through a published process with consultation documents, which makes the reasoning unusually visible compared with most jurisdictions.

Availability has historically lagged Australia for several products in this class, and unfunded access at full private cost is the common route.

The route people actually use

In practice the access question in New Zealand resolves into three sub-questions: whether a prescription can be obtained, whether it will be funded, and whether the product is currently in supply. Those have different answers and different remedies, and conflating them is the commonest reason a member gets stuck.

If funding is the obstacle, the appeal discussion in Access is more useful than another consultation. If supply is the obstacle, the national shortage register — where one exists — is the only source worth reading.

What this page will not help with

This page does not describe how to obtain unlicensed material, and this community does not assist with that. It also does not tell you whether something is legal for you to possess, because that depends on facts about you that a documentation page cannot know.

Research-use-only material is not a licensed medicine in New Zealand or anywhere else we are aware of.

Contributing

Regional pages are maintained by members in the region. If you can confirm or contradict anything here from a primary source, post in the regional category with the source and the date. An undated claim in this area is worse than no claim, and we will ask for the date.

Revision history

2026-05-03	crossref_check	Plain-language pass on the opening section after feedback from a newcomer.
2026-03-01	dexa_twice_yearly	Added the limitations paragraph. The page previously implied more certainty than the sources carry.
2025-10-04	a.salcedo	Reverted an unsourced change and asked the editor to re-apply it with a citation.
2025-06-06	n.rowntree	Added the worked example that the review thread asked for.
2025-03-20	impurity_table	Initial promotion from the source topic. Structure taken from the marked solution.

Every edit to a maintained document records its author and a note explaining the change. An edit without a note may be reverted by any wiki editor under R9, and the revert is logged. Disagreements about content belong on the source topic rather than in the revision history (R10).

Scope and expiry

Regulatory and prescription position

Coverage and cost

The route people actually use

What this page will not help with

Contributing

Revision history

Related documents